The possibility that adult bone marrow cells (BMCs) retain a remarkable degree of developmental plasticity and acquire the cardiomyocyte lineage after infarction has been challenged, and the notion of BMC transdifferentiation has been questioned. The center of the controversy is the lack of unequivocal evidence in favor of myocardial regeneration by the injection of BMCs in the infarcted heart. Because of the interest in cell-based therapy for heart failure, several approaches including gene reporter assay, genetic tagging, cell genotyping, PCR-based detection of donor genes, and direct immunofluorescence with quantum dots were used to prove or disprove BMC transdifferentiation. Our results indicate that BMCs engraft, survive, and grow within the spared myocardium after infarction by forming junctional complexes with resident myocytes. BMCs and myocytes express at their interface connexin 43 and N-cadherin, and this interaction may be critical for BMCs to adopt the cardiomyogenic fate. With time, a large number of myocytes and coronary vessels are generated. Myocytes show a diploid DNA content and carry, at most, two sex chromosomes. Old and new myocytes show synchronicity in calcium transients, providing strong evidence in favor of the functional coupling of these two cell populations. Thus, BMCs transdifferentiate and acquire the cardiomyogenic and vascular phenotypes restoring the infarcted heart. Together, our studies reveal that locally delivered BMCs generate de novo myocardium composed of integrated cardiomyocytes and coronary vessels. This process occurs independently of cell fusion and ameliorates structurally and functionally the outcome of the heart after infarction. myocardial infarction ͉ myocardial regeneration ͉ stem cells ͉ transdifferentiation T o date, the hematopoietic stem cell appears to be the most versatile stem cell in crossing lineage boundaries and the most prone to break the law of tissue fidelity (1). Early studies on c-kit-positive bone marrow cell (BMC) differentiation into myocardium have generated great enthusiasm (2, 3), but other observations have rejected the initial results (4-6) and promoted a wave of skepticism about the therapeutic potential of BMCs for the injured heart. The major criticisms include: (i) lack of utilization of genetic markers for the recognition of donor BMCs and their progeny; (ii) inaccurate interpretation of the original data due to autofluorescence artifacts; and (iii) the possibility that myocyte regeneration is mediated by fusion of BMCs with resident myocytes rather than BMC transdifferentiation. To address these important questions and demonstrate reproducibility of results, four laboratories with complementary expertise have undertaken a series of joined experiments to acquire information on the plasticity of BMCs and their therapeutic potential for the infarcted heart.
T o date, the hematopoietic stem cell appears to be the most versatile stem cell in crossing lineage boundaries and the most prone to break the law of tissue fidelity (1) . Early studies on c-kit-positive bone marrow cell (BMC) differentiation into myocardium have generated great enthusiasm (2, 3) , but other observations have rejected the initial results (4-6) and promoted a wave of skepticism about the therapeutic potential of BMCs for the injured heart. The major criticisms include: (i) lack of utilization of genetic markers for the recognition of donor BMCs and their progeny; (ii) inaccurate interpretation of the original data due to autofluorescence artifacts; and (iii) the possibility that myocyte regeneration is mediated by fusion of BMCs with resident myocytes rather than BMC transdifferentiation. To address these important questions and demonstrate reproducibility of results, four laboratories with complementary expertise have undertaken a series of joined experiments to acquire information on the plasticity of BMCs and their therapeutic potential for the infarcted heart.
In this effort, BMCs for myocardial regeneration were obtained from three transgenic mice. In the first, EGFP was driven by the ubiquitous ␤-actin promoter; in the second, EGFP was driven by the cardiac-specific ␣-myosin-heavy-chain (␣-MHC) promoter; and in the third, a c-myc-tagged nuclear-targeted-Akt transgene was driven by the ␣-MHC-promoter (7) . With the first category of BMC (␤-actin-EGFP), all cardiac cells formed by BMC differentiation were expected to express EGFP; with the second category of BMCs (␣-MHC-EGFP), only myocytes formed by BMC differentiation were expected to express EGFP; and with the third category of BMCs (␣-MHC-c-myc-tagged-nuc-Akt), only myocytes formed by BMC differentiation were expected to express c-myc in their nuclei. In all cases, male BMCs were injected in wild-type female infarcted mice so that cell genotyping would allow the distinction between resident female cardiac cells and newly generated male cardiac cells. These strategies allowed us to determine the destiny of BMCs within the recipient heart by genetic tagging with EGFP, cell fate tracking with ␣-MHC-EGFP and ␣-MHC-c-myc, and cell genotyping by sex-chromosome identification.
Results

Engraftment of BMCs.
A premise of these studies was the use of a methodology in which immunolabeling of proteins was obtained in the absence of autofluorescence inherent in tissue sections of formalin-fixed myocardium. This objective was achieved by implementing a technology by which primary antibodies are directly labeled by quantum dots (QD). This procedure eliminates the need for secondary antibody and avoids the interference of autofluorescence in the specificity of the reaction [see supporting information (SI) Fig. 6 ].
BMC differentiation and acquisition of the cardiogenic fate involves the engraftment of the donor cells within the host myocardium. Within 12-48 h after infarction and cell implantation, donor BMCs were seeded within the myocardium of the border zone and were, in part, integrated structurally with resident cells (SI Fig. 7 ). Junctional and adhesion complexes were detected between BMCs and between BMCs and adjacent myocytes and fibroblasts ( Fig. 1 A and B) . Myocytes and fibroblasts function as supporting cells within the cardiac stem cell niches (8) , suggesting that BMCs form niche-like structures within the recipient myocardium (9) .
A large proportion of engrafted BMCs was cycling as documented by BrdU labeling and expression of Ki67. Phospho-H3 was also detected in dividing BMCs ( Fig. 1 C-E) . Conversely, in the absence of engraftment, BMCs died by apoptosis (Fig. 1 F and G) . Apoptosis was restricted to BMCs that failed to express connexin 43 and N-cadherin. At 48 h after cell implantation, an average 63 Ϯ 6% BrdU labeling of engrafted BMCs was measured. For each BMC category, cell proliferation increased progressively from 12 to 24-36 and 48 h, whereas cell apoptosis was gradually attenuated (SI Fig. 7) . In each case, Ϸ25% or 14,000 of the 60,000 injected BMCs were present in the viable tissue of the border zone at 2 days (SI Fig. 7) .
To confirm the ability of BMCs to home to the myocardium, these cells were injected intravenously shortly after coronary artery ligation, and their localization in the heart was examined 1-2 (n ϭ 7) and 4 (n ϭ 4) days later. In all cases, clusters of BMCs were found in the infarct border zone where a fraction of these cells acquired the myocyte lineage. These cells were integrated within the recipient myocardium because connexin 43 was expressed at the interface between new and old myocytes. BMC-derived myocytes carried the Y chromosome. Additionally, single and doublets of BMCs were scattered in the viable myocardium adjacent to the infarct (SI Fig. 7) . Thus, BMCs engraft, survive, and grow within the myocardium by forming junctional complexes among them and with resident myocytes and fibroblasts.
BMCs Acquire the Cardiogenic Fate. The high level of proliferation in engrafted BMCs distinguished these cell clusters from resident cardiac niches that are composed predominantly of quiescent cells (8) . At 12 h, BMCs were mostly CD45-positive, but at 24-36 h, a large subset of BMCs was CD45-negative, and the absence of CD45 was even more evident at 48 h (Fig. 2 A-D) . The presence of Y chromosome and/or EGFP was used to distinguish resident from injected CD45-positive cells. The expression of connexin 43 accompanied the phenotypic conversion of BMCs into cardiac cells (Fig. 2C) . Markers of myocytes, endothelial cells (ECs), and smooth muscle cells (SMCs) were detected in the engrafted BMCs (Fig. 2  E-J) , suggesting that the myocardial microenvironment changed the fate of BMCs. Nonengrafted CD45-positive BMCs were hardly detectable at 5 days, and the few CD45-positive cells were of recipient origin. Thus, BMCs home to the myocardium where they rapidly lose the hematopoietic phenotype and acquire the cardiomyocyte lineage.
Gap Junctions and BMC Destiny. Translocation of calcium from myocytes to BMCs via gap junctions may have profound effects on their acquisition of the myocyte lineage, growth, and differentiation. Cell coupling was analyzed in vitro by two-photon microscopy after loading BMCs with the red fluorescent dye DiI, which integrates stably in the cell membrane. Labeled BMCs (red) were plated with rat neonatal myocytes, which were loaded with the green fluorescent dye calcein that translocates to neighboring cells through the generation of gap junctions (10) . The appearance of green fluorescence in BMCs indicated the transfer of calcein from myocytes via junctional complexes ( Fig. 3 A-C) . For real-time dye transfer, cascade blue, which also cannot diffuse spontaneously, was injected in BMCs or myocytes, and the passage of the dye from one cell to the other was recorded. This event occurred in Ͻ3 min ( Fig.  3 D-N) . When BMCs were loaded with rhodamine-labeled dextran, this high-molecular-mass dye (70,000 Da) did not transfer to myocytes (Fig. 3O ).
With time, BMCs differentiated into myocytes that contracted spontaneously or after stimulation at 1 Hz (Fig. 3 P-U) . Additionally, connexin 43 was identified at the interface between EGFPnegative neonatal myocytes and EGFP-positive-myocytes derived from BMCs of ␣-MHC-EGFP mice ( Fig. 3 V-X) . A diploid DNA content was measured in new myocytes excluding fusion events. Thus, BMCs and myocytes become electrically coupled, and this may be critical for BMCs to adopt the cardiomyogenic fate.
BMC Differentiation. Three classes of male BMCs were used to induce myocardial regeneration in female infarcted mice (SI Fig. 8 ).
One cell category was EGFP-positive, and the other two were EGFP-negative (SI Fig. 9 ). Importantly, the presence of the Y chromosome distinguished all bone marrow-derived male cardiac cells from resident female cells (SI Fig. 9 ). Engraftment of BMCs shortly after their delivery was followed by myocardial regeneration (Fig. 4 A-F and SI Figs. 10 and 11), which expanded from 5 to 10 and 30 days after infarction. The regenerated myocardium had two consequences on cardiac remodeling; it attenuated the inflammatory response acutely-subacutely and prevented largely scar formation (SI Fig. 12 ).
At the three time points, regenerated myocytes, ECs, and SMCs expressed the different transgenes in the anticipated fashion. BMCs obtained from ␤-actin-EGFP mice formed a myocardium in which cardiomyocytes, ECs, and SMCs were mostly EGFP-positive ( Fig.  4C and SI Fig. 11 ). When the expression of EGFP or c-myc tag was regulated by the ␣-MHC-promoter, the transgenes were detected exclusively in myocytes (Fig. 4 A, B , E, and F and SI Fig. 10) . However, the recognition of the Y chromosome allowed us to document that vascular structures were the result of BMC differentiation (Fig. 4 E and F) .
The number of myocytes formed by BMCs exceeded the number of myocytes lost with infarction (SI Fig. 13 ). Although the postnatal maturation of the myocardium in rodents is completed at 1 month, the myocytes derived from BMCs failed to reach the adult phenotype. The proportion of binucleated myocytes increased at 1 month (SI Fig. 13 ) but was lower than that present in the adult myocardium. Similarly, the number of capillaries was markedly lower than in the adult heart, but arteriolar density exceeded the values of the developing and mature myocardium (SI Fig. 13 ). Thus, adult BMCs differentiate into the cardiac lineages and repair, in part, the infarcted heart. BMC Differentiation and Cell Fusion. To determine the presence of cell fusion, DNA content per nucleus and the number of sex chromosomes were measured in newly formed myocytes, SMCs, and ECs. Whereas sex chromosomes were evaluated in the progeny of the three classes of BMCs, DNA content per nucleus was determined in myocytes, ECs, and SMCs formed by BMCs from ␤-actin-EGFP mice; the localization of EGFP allowed the recognition of all BMC-derived cardiac cells.
EGFP-positive-mononucleated and binucleated myocytes and EGFP-positive ECs and SMCs had 2n DNA content per nucleus (SI Fig. 14) . Moreover, regenerated myocytes, ECs, and SMCs showed at most one Y and one X chromosome, documenting the male genotype of the restored myocardium (SI Fig. 14) . Conversely, the myocytes of the border zone possessed, at most, two X chromosomes, demonstrating that these cells retained the female genotype and did not participate in fusion events (SI Fig. 14) . Fusion between adult myocytes, 25,000 m 3 in volume or larger, and BMCs would result in the generation of a myocyte progeny of nearly the same size, which was not the case. The new myocytes had volumes that varied from 100 to 2,500 m 3 . Thus, c-kit-positive-BMCs are capable of restoring infarcted myocardium independently from cell fusion.
Molecular Documentation of BMC Differentiation. To strengthen the morphological results, the presence of the reporter genes EGFP and c-myc was demonstrated by PCR of genomic DNA extracted from infarcted hearts. DNA sequences for EGFP and c-myc tag were detected in all treated animals at 5, 10, and 30 days after infarction and BMC implantation. DNA bands had the expected molecular mass and sequence ( Fig. 5A and SI Fig. 15 ). RT-PCR was used to identify transcripts for EGFP and c-myc tag. Again, EGFP and c-myc tag mRNAs were found in all samples containing newly formed myocardium. RT-PCR products had the anticipated molecular mass and sequence ( Fig. 5B and SI Fig. 15 ). Importantly, protein levels for EGFP and c-myc-tag were identified by Western blotting (Fig. 5C) .
The detection of transcripts and proteins for EGFP and c-myc-tag in infarcted hearts treated with BMCs from mice in which these transgenes were driven by the ␣-MHC promoter provided strong evidence in favor of BMC transdifferentiation and active cardiomyogenesis. The recognition of EGFP mRNA and protein in infarcted hearts injected with BMCs from mice in which EGFP was under the control of the ␤-actin-promoter confirmed active engraftment of the donor cells and was consistent with the histological results. Additionally, EGFP-positive and c-myc-positive myocytes were isolated from the infarcted region of treated hearts (SI Fig. 16 ). Collectively, these data document that BMCs retain a degree of developmental plasticity and acquire the myogenic and vascular phenotypes, restoring, in part, the infarcted myocardium.
Physiological Documentation of BMC Differentiation. An important question was whether formed myocytes were functionally competent electrically and mechanically. Regenerated myocytes within the infarct and surviving myocytes away from the infarct were isolated and their physiological properties determined. Shortly after injection, cells positive for c-kit, CD45, and EGFP were identified, and these cells did not show electrical properties of developing myocytes or contracted in response to electrical stimulation (Fig. 5D) . At 15-30 days, small myocytes were identified, and these BMC-derived myocytes exhibited electrical characteristics similar to spared myocytes but showed a prolongation of the action potential and enhanced cell shortening (Fig. 5 E-H) . A remaining issue concerned whether the new myocytes were integrated structurally and functionally with resident myocytes in vivo and participated in ventricular performance. Connexin 43 was detected between the viable and repaired myocardium. Importantly, connexin 43 was shared by preexisting and new myocytes, documenting the structural integration between resident female myocytes and new male myocytes (SI Fig. 16 ).
The functional integration of regenerated EGFP-positivemyocytes with the surrounding myocardium was documented by an ex vivo preparation and two-photon microscopy in treated hearts at 1 month. The heart was perfused retrogradely through the aorta with an oxygenated Tyrode solution containing the calcium indicator Rhod-2. The heart was then stimulated at 1 Hz, and calcium transient was clearly present in EGFP-positive BMC-derived myocytes and EGFP-negative mouse myocytes. The synchronicity in calcium transients between these two myocyte populations provided strong evidence in favor of the functional coupling of old and new myocytes (Fig. 5I) .
The injection of BMCs and myocardial regeneration restored, in part, the loss of contraction in the infarcted region of the wall, documented echocardiographically at 30 days (SI Fig. 17) . Additionally, cardiac repair reduced chamber volume and increased the wall thickness-to-chamber radius ratio (SI Fig. 17) . Hemodynamically, myocardial regeneration attenuated the increase in LVEDP, improved LVDP and positive and negative dP/dt and decreased diastolic wall stress (SI Fig. 17) . Thus, BMCs adopt the cardiomyogenic fate structurally, electrically, and mechanically, improving the function of the damaged heart. Paracrine Effects of BMCs. The possibility that BMCs activate growth and differentiation of resident progenitor cells or induce angiogenesis through the recruitment of circulating BMCs has been suggested (3, 11, 12) . Therefore, we measured the formation of myocytes and vessels in the border zone. Because BrdU was given to the animals throughout, newly formed structures generated by endogenous mechanisms had to be female in origin, positive for BrdU, and negative for EGFP and c-myc. In all cases, the extent of myocyte and vessel formation was comparable with that in untreated infarcted mice at 30 days (SI Fig. 18 ). Moreover, the degree of cell replication determined by Ki67 and MCM5 at sacrifice was comparable in cell-treated and untreated mice (SI Fig. 18 ). Although our results do not support a paracrine effect of BMCs, factors released in the infarcted region could have contributed significantly to the mechanisms of cardiac repair. Our data do not exclude this likely possibility. 
Discussion
The results of the current study indicate that a category of adult cells from the bone marrow shares a degree of developmental plasticity commonly seen in embryonic stem cells; c-kit-positive BMCs engraft in proximity to the infarcted myocardium and differentiate into cells of the cardiogenic lineage, forming functionally competent cardiomyocytes and vascular structures. The regenerated myocardium positively interferes with the development of the myopathy after infarction, attenuating the dramatic changes in ventricular size and shape and the progressive deterioration in cardiac function that occur chronically after infarction (13) . Our data strongly suggest that adult BMCs implanted in the infarcted heart lose the hematopoietic fate and integrate with the host myocardium by establishing a microenvironment necessary for the engrafted cells to adopt the cardiac destiny and form de novo myocardium. These observations are important because small double-blind multicenter clinical trials in which mononuclear BMCs have been administered to patients with acute and chronic ischemic heart failure have recently been completed (14, 15) . Despite positive results, the mechanism by which mononuclear BMCs improve the outcome of acute myocardial infarction and chronic ischemic cardiomyopathy in humans remains unclear. Currently, effort is being made to initiate large clinical trials, although uncertainties persist about the actual effects of BMCs on the decompensated heart. Our results suggest that myocardial regeneration is a likely possibility.
The early studies on BMC transdifferentiation and cardiac repair (2, 3, 16, 17) have been followed by numerous negative reports that have rejected the notion of stem cell plasticity and the relevance of BMCs for the management of the human disease (4-6). The therapeutic potential of BMCs was questioned at multiple levels, which included the lack of implementation of genetic strategies for the recognition of the destiny of BMCs in the infarcted heart together with the misinterpretation of immunocytochemical results (18, 19) . These limitations have been overcome here by the utilization of three categories of BMCs with distinct genotypic characteristics and the use of a methodology that excludes autofluorescence artifacts. An important variable that has frequently been neglected experimentally and may explain contrasting results concerns the preparation, viability, and modality of injection of BMCs (20) . Recently, the clinical application of improperly collected BMCs (21) has resulted in the absence of benefit in patients with acute myocardial infarction (22) . Conversely, carefully acquired, stored, and administered BMCs not only improve ventricular function chronically after infarction but increase survival in patients with heart failure after infarction (23) .
Importantly, fusion of BMCs with resident cardiac cells has been proposed as the only mechanism by which cells of bone marrow origin can form myocytes and promote tissue repair (4-6). The documentation that BMCs fuse with resident cardiomyocytes is technically demanding. This involves the identity of the fused cell, the functional competence of the progeny, the recognition of the fusion partner, and the demonstration that the converted cell is a hybrid (24) . The fate of BMCs after their injection in the infarcted heart has been characterized with the Cre-Lox genetic system. Unfortunately, the Cre-Lox model is not perfect. The unmodified Cre-recombinase present in progenitor cells can cross the membrane of the recipient cell (25) , mimicking fusion events. Also, this enzyme can be translocated via nanotubules (26) from BMCs carrying the Cre-recombinase to the resident cells, giving the false impression of cell fusion. Therefore, we have excluded cell fusion by documenting a diploid DNA content together with one set only of sex chromosomes in nuclei of newly formed myocytes, SMCs, and ECs. The regenerated myocytes are functionally competent and significantly smaller than the host cells, further excluding fusion events. In this regard, no viable partner cells are available for fusion in transmural myocardial infarcts. Fusion history may be concealed by reductive mitosis (27) in which the fused cells would expel part of their chromosomal DNA and convert tetraploid cells into diploid cells, masking the formation of heterokaryons. However, there is no demonstration of this unusual cell behavior either in vitro or in vivo.
The possibility that BMC therapy of the infarcted heart exerts its beneficial effects by activation of resident progenitor cells has been suggested (2, 3, 11, 12) . According to this hypothesis, BMCs may contribute indirectly to cardiac regeneration by releasing a variety of peptides that exert a paracrine action on the myocardium and its resident cells. The most convincing example in favor of a paracrine effect of BMCs was shown recently (3). The current work does not exclude this indirect role of BMCs in cardiac repair. Collectively, these findings point to the notion that BMCs adopt the cardiac phenotype and potentiate the growth reserve of the adult heart, emphasizing the therapeutic import of BMCs for heart failure in humans.
Materials and Methods
Myocardial infarction was induced in wild-type mice, and BMCs were injected in the region bordering the infarct. Myocardial regeneration was evaluated by immunocytochemistry, molecular biology, and FISH analysis. The newly formed myocytes were characterized electrically and mechanically. For additional information, see SI Materials and Methods.
